Precision BioSciences is also currently evaluating PBGENE-PMM, a first-of-its-kind treatment for m.3243 associated mitochondrial disease, in pre-clinical studies.

DURHAM, N.C., November 21, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits ...